About Contact Us Careers

Dystonia Drugs Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 3473
Published Date: Aug 27, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the Dystonia Drugs Landscape

Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Ipsen Biopharmaceuticals, Inc.
Revance Therapeutics, Inc.
Solstice Neurosciences LLC
US Worldmeds, LLC
Merz Pharma GmbH & Co. KGaA
Medytox, Inc.
Novartis AG
Mylan N.V.
GlaxoSmithKline plc

Browse Key Market Insights with Data Illustration:

Dystonia Drugs Market Size & Share, Growth Report 2036

In the News

· October 14, 2020- Revance Therapeutics, Inc. reported positive results from its ASPEN-1 Phase 3 trial of DaxibotulinumtoxinA for injection in treating cervical dystonia, which is a chronic condition affecting neck muscles.

Author Credits: Radhika Pawar

Report ID: 3473
Published Date: Aug 27, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of dystonia drugs is assessed at USD 909.87 million.

Dystonia Drugs Market size was over USD 872.19 million in 2023 and is anticipated to reach USD 1.72 billion by 2036, growing at around 5.4% CAGR during the forecast period i.e., between 2024-2036. The market growth is driven by growing prevalence of dystonia disorders and increasing number of incidences of musculoskeletal disorders.

Asia Pacific is expected to dominate majority revenue share by 2036, on the back of increase in the geriatric population, large patient pool, and rapid growth of pharmaceutical sector in countries such as China, Japan and India.

The major players in the market are Pfizer, Inc., Ipsen Biopharmaceuticals, Inc., Revance Therapeutics, Inc., Solstice Neurosciences LLC, US Worldmeds, LLC, and others.

Inquiry Before Buying Request Free Sample